Profusa CEO Says 'Co To Capitalize On The Near-Term European And U.S. Lumee Oxygen Opportunity To Deliver 2026 Potential Revenue Of $500K To $2M And $9M To $13M Potential Revenue In 2027

Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces financial results for the third quarter ended September 30, 2025, and provides business highlights.

Ben Hwang, Ph.D., Profusa's Chairman and CEO, said, "It was an extremely busy four months for the team, and we are proud of our achievements in such a short period of time. In the third quarter, we achieved a significant milestone for the company with the completion of our merger with NorthView Acquisition Corporation. We recapitalized our balance sheet, reducing net debt from $34 million to $14 million as of October 31, 2025. Since the closing of the merger on July 11, 2025, we have raised $7 million in gross proceeds through our Equity Line of Credit ("ELOC") transaction and an additional $2 million in convertible debt.

"We also delivered key operational milestones including the build-out of our manufacturing capabilities; entered several potential distributor and clinical and commercial collaborations; and built a team focused on executing the company's strategy.

"We now lead Profusa forward as we execute on our plans to potentially achieve $200 to $250 million in revenue by 2030; capitalize on the near-term European and US Lumee oxygen opportunity to deliver 2026 potential revenue of $0.5 to $2 million and $9 to $13 million potential revenue in 2027," concluded Mr. Hwang.